title: Effects of corneal thickness on the intraocular penetration of travoprost 0.004%.
abstract: OBJECTIVE
  To determine whether the intraocular penetration of travoprost 0.004% is affected by central corneal thickness.
  
  
  METHODS
  Sixty-four patients who were scheduled for cataract surgery without any other ophthalmologic pathology of significance were enrolled in this study. At 120 min before surgery, one drop of travoprost 0.004% was instilled in the eye to be operated on. At the start of surgery, a sample of aqueous humour was extracted to subsequently determine its AL-5848 concentration. These concentrations were compared among three groups of patients established according to central corneal thickness measurements obtained by ultrasound pachymetry.
  
  
  RESULTS
  Mean AL-5848 concentrations were 3.27±2.03 ng/ml in Group I (CCT<511 microns), 3.27±2.44 ng/ml in Group II (CCT≥511 and ≤574 microns), and 2.73±2.15 ng/ml in Group III (CCT>574 microns), indicating no significant differences among the groups.
  
  
  CONCLUSIONS
  We were unable to demonstrate the greater or lesser penetration of travoprost depending on corneal thickness, which could explain differences in patient responses to this drug.
authors.affiliation: Servicio de Oftalmologia, Hospital Clinico San Carlos, Departamento de Oftalmologia, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain. martinezcasa@ya.com
authors.forename: J M
authors.initials: JM
authors.lastname: Martinez-de-la-Casa
authors.forename: O
authors.initials: O
authors.lastname: Rayward
authors.forename: F
authors.initials: F
authors.lastname: Saenz-Frances
authors.forename: E
authors.initials: E
authors.lastname: Santos-Bueso
authors.forename: C
authors.initials: C
authors.lastname: Mendez-Hernandez
authors.forename: R
authors.initials: R
authors.lastname: Herrero-Vanrell
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Feijoo
authors.forename: J
authors.initials: J
authors.lastname: Garcia-Sanchez
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001082:Aqueous Humor / Q000378:metabolism*; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D003315:Cornea / Q000033:anatomy & histology* / Q000378:metabolism; D005260:Female; D005901:Glaucoma / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008297:Male; D000069557:Travoprost
chemical_list: D000959:Antihypertensive Agents; D003008:Cloprostenol; D000069557:Travoprost